Bristol Likes What It Sees In Five Prime, Invests More In CSF1R Program
This article was originally published in Scrip
Executive Summary
You may also be interested in...
A Virtuous Cycle: What The Immuno-Oncology Revolution Means For Other Disease Areas
Execs from Merck, Pfizer, Bristol, Abbvie and smaller biopharmas weigh in on how developments in cancer research may benefit other disease areas, especially autoimmune and neurological conditions.
Five Prime Bounces Back With Good Spin On Cabiralizumab Data
Bristol's new Phase I study of Opdivo with Five Prime's cabiralizumab in second-line pancreatic cancer restored faith in the combo for some investors, as did a full presentation of pancreatic cancer data slated for SITC.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.